Fondaparinux

An overview

Sunil K. Nadar, Deepak Goyal, Eduard Shantsila, Pritwish Banerjee, Gregory Y H Lip

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Fondaparinux is a synthetic pentasaccharide belonging to a new group of anticoagulants that inhibit thrombin formation by inhibiting Factor Xa, which is located at the crossing of both the intrinsic and extrinsic pathways. It has a favorable pharmacokinetic profile, and its effect is predictable and the drug does not need platelet monitoring. Current evidence suggest that fondaparinux is as effective as, if not more than, enoxaparin in the prevention of venous thromboembolism in the postoperative period. It has also been found to have similar effectiveness to enoxaparin and unfractionated heparin in the treatment of venous and pulmonary embolism, respectively. In the field of cardiology, studies have demonstrated that in the setting of acute coronary syndromes, treatment with fondaparinux is not inferior to enoxaparin in preventing major cardiac outcomes, but it is associated with lower risk of bleeding complications, irrespective of the use of percutaneous coronary intervention. During percutaneous coronary intervention, there is a slightly increased risk of catheter thrombosis, which is removed when used along with unfractionated heparin. However, in patients with ST-elevation myocardial infarction, the benefit has been shown in those either receiving thrombolysis or not undergoing any revascularization, but not in subjects undergoing primary percutaneous coronary intervention where unfractionated heparin is still preferred.

Original languageEnglish
Pages (from-to)577-585
Number of pages9
JournalExpert Review of Cardiovascular Therapy
Volume7
Issue number6
DOIs
Publication statusPublished - Jun 2009

Fingerprint

Enoxaparin
Percutaneous Coronary Intervention
Heparin
Factor Xa
Venous Thromboembolism
Acute Coronary Syndrome
Cardiology
Pulmonary Embolism
Postoperative Period
Thrombin
Anticoagulants
Thrombosis
Blood Platelets
Catheters
Pharmacokinetics
Hemorrhage
Therapeutics
Pharmaceutical Preparations
fondaparinux

Keywords

  • Anticoagulant
  • Factor Xa
  • Fondaparinux

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Nadar, S. K., Goyal, D., Shantsila, E., Banerjee, P., & Lip, G. Y. H. (2009). Fondaparinux: An overview. Expert Review of Cardiovascular Therapy, 7(6), 577-585. https://doi.org/10.1586/erc.09.19

Fondaparinux : An overview. / Nadar, Sunil K.; Goyal, Deepak; Shantsila, Eduard; Banerjee, Pritwish; Lip, Gregory Y H.

In: Expert Review of Cardiovascular Therapy, Vol. 7, No. 6, 06.2009, p. 577-585.

Research output: Contribution to journalReview article

Nadar, SK, Goyal, D, Shantsila, E, Banerjee, P & Lip, GYH 2009, 'Fondaparinux: An overview', Expert Review of Cardiovascular Therapy, vol. 7, no. 6, pp. 577-585. https://doi.org/10.1586/erc.09.19
Nadar SK, Goyal D, Shantsila E, Banerjee P, Lip GYH. Fondaparinux: An overview. Expert Review of Cardiovascular Therapy. 2009 Jun;7(6):577-585. https://doi.org/10.1586/erc.09.19
Nadar, Sunil K. ; Goyal, Deepak ; Shantsila, Eduard ; Banerjee, Pritwish ; Lip, Gregory Y H. / Fondaparinux : An overview. In: Expert Review of Cardiovascular Therapy. 2009 ; Vol. 7, No. 6. pp. 577-585.
@article{590564790b934120af03a5069410a79d,
title = "Fondaparinux: An overview",
abstract = "Fondaparinux is a synthetic pentasaccharide belonging to a new group of anticoagulants that inhibit thrombin formation by inhibiting Factor Xa, which is located at the crossing of both the intrinsic and extrinsic pathways. It has a favorable pharmacokinetic profile, and its effect is predictable and the drug does not need platelet monitoring. Current evidence suggest that fondaparinux is as effective as, if not more than, enoxaparin in the prevention of venous thromboembolism in the postoperative period. It has also been found to have similar effectiveness to enoxaparin and unfractionated heparin in the treatment of venous and pulmonary embolism, respectively. In the field of cardiology, studies have demonstrated that in the setting of acute coronary syndromes, treatment with fondaparinux is not inferior to enoxaparin in preventing major cardiac outcomes, but it is associated with lower risk of bleeding complications, irrespective of the use of percutaneous coronary intervention. During percutaneous coronary intervention, there is a slightly increased risk of catheter thrombosis, which is removed when used along with unfractionated heparin. However, in patients with ST-elevation myocardial infarction, the benefit has been shown in those either receiving thrombolysis or not undergoing any revascularization, but not in subjects undergoing primary percutaneous coronary intervention where unfractionated heparin is still preferred.",
keywords = "Anticoagulant, Factor Xa, Fondaparinux",
author = "Nadar, {Sunil K.} and Deepak Goyal and Eduard Shantsila and Pritwish Banerjee and Lip, {Gregory Y H}",
year = "2009",
month = "6",
doi = "10.1586/erc.09.19",
language = "English",
volume = "7",
pages = "577--585",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Fondaparinux

T2 - An overview

AU - Nadar, Sunil K.

AU - Goyal, Deepak

AU - Shantsila, Eduard

AU - Banerjee, Pritwish

AU - Lip, Gregory Y H

PY - 2009/6

Y1 - 2009/6

N2 - Fondaparinux is a synthetic pentasaccharide belonging to a new group of anticoagulants that inhibit thrombin formation by inhibiting Factor Xa, which is located at the crossing of both the intrinsic and extrinsic pathways. It has a favorable pharmacokinetic profile, and its effect is predictable and the drug does not need platelet monitoring. Current evidence suggest that fondaparinux is as effective as, if not more than, enoxaparin in the prevention of venous thromboembolism in the postoperative period. It has also been found to have similar effectiveness to enoxaparin and unfractionated heparin in the treatment of venous and pulmonary embolism, respectively. In the field of cardiology, studies have demonstrated that in the setting of acute coronary syndromes, treatment with fondaparinux is not inferior to enoxaparin in preventing major cardiac outcomes, but it is associated with lower risk of bleeding complications, irrespective of the use of percutaneous coronary intervention. During percutaneous coronary intervention, there is a slightly increased risk of catheter thrombosis, which is removed when used along with unfractionated heparin. However, in patients with ST-elevation myocardial infarction, the benefit has been shown in those either receiving thrombolysis or not undergoing any revascularization, but not in subjects undergoing primary percutaneous coronary intervention where unfractionated heparin is still preferred.

AB - Fondaparinux is a synthetic pentasaccharide belonging to a new group of anticoagulants that inhibit thrombin formation by inhibiting Factor Xa, which is located at the crossing of both the intrinsic and extrinsic pathways. It has a favorable pharmacokinetic profile, and its effect is predictable and the drug does not need platelet monitoring. Current evidence suggest that fondaparinux is as effective as, if not more than, enoxaparin in the prevention of venous thromboembolism in the postoperative period. It has also been found to have similar effectiveness to enoxaparin and unfractionated heparin in the treatment of venous and pulmonary embolism, respectively. In the field of cardiology, studies have demonstrated that in the setting of acute coronary syndromes, treatment with fondaparinux is not inferior to enoxaparin in preventing major cardiac outcomes, but it is associated with lower risk of bleeding complications, irrespective of the use of percutaneous coronary intervention. During percutaneous coronary intervention, there is a slightly increased risk of catheter thrombosis, which is removed when used along with unfractionated heparin. However, in patients with ST-elevation myocardial infarction, the benefit has been shown in those either receiving thrombolysis or not undergoing any revascularization, but not in subjects undergoing primary percutaneous coronary intervention where unfractionated heparin is still preferred.

KW - Anticoagulant

KW - Factor Xa

KW - Fondaparinux

UR - http://www.scopus.com/inward/record.url?scp=68849093755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68849093755&partnerID=8YFLogxK

U2 - 10.1586/erc.09.19

DO - 10.1586/erc.09.19

M3 - Review article

VL - 7

SP - 577

EP - 585

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 6

ER -